A federal jury in Texas ordered Abbott Laboratories to pay $1.6 billion for infringing on the patent of Johnson & Johnson"s arthritis treatment Remicade [infliximab]. J&J had claimed that Abbott"s Humira [adalimumab] infringed a patent that J&J"s Centocor Ortho Biotech unit held for rival treatment Remicade while Abbott claimed that the patent doesn"t cover the human antibodies used in Humira.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지